Stock HYPE3 HYPERA S.A.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Hypera S.A.

Equities

HYPE3

BRHYPEACNOR0

Pharmaceuticals

Delayed Sao Paulo
Other stock markets
 11:23:05 03/05/2024 pm IST 		5-day change 1st Jan Change
30.12 BRL +1.11% Intraday chart for Hypera S.A. +5.53% -15.72%
29/04 Transcript : Hypera S.A., Q1 2024 Earnings Call, Apr 29, 2024
27/04 Hypera S.A. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 22,501 21,688 17,873 28,615 22,617 18,859 - -
Enterprise Value (EV) 1 21,657 22,481 22,947 35,360 29,998 26,439 25,487 25,250
P/E ratio 19.6 x 16.9 x 11.2 x 17 x 13.7 x 10.4 x 9.05 x 7.86 x
Yield 3% 3.42% 4.35% 2.72% 3.44% 4.26% 4.93% 6.6%
Capitalization / Revenue 6.83 x 5.3 x 3.01 x 3.79 x 2.86 x 2.18 x 1.97 x 1.81 x
EV / Revenue 6.57 x 5.5 x 3.86 x 4.69 x 3.79 x 3.06 x 2.66 x 2.43 x
EV / EBITDA 18 x 15.6 x 10.9 x 13.3 x 10.9 x 8.76 x 7.54 x 6.88 x
EV / FCF 46.9 x -30.2 x 50.6 x 66.8 x 19 x 15 x 11.5 x 10.1 x
FCF Yield 2.13% -3.31% 1.98% 1.5% 5.27% 6.68% 8.7% 9.91%
Price to Book 2.59 x 2.35 x 1.84 x 2.68 x 1.96 x 1.5 x 1.38 x 1.27 x
Nbr of stocks (in thousands) 6,30,453 6,33,218 6,32,219 6,33,064 6,32,654 6,33,057 - -
Reference price 2 35.69 34.25 28.27 45.20 35.75 29.79 29.79 29.79
Announcement Date 07/03/20 26/02/21 24/02/22 16/02/23 13/03/24 - - -
1BRL in Million2BRL
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 3,295 4,089 5,937 7,546 7,915 8,649 9,573 10,411
EBITDA 1 1,206 1,440 2,102 2,651 2,756 3,017 3,380 3,670
EBIT 1 1,086 1,319 1,968 2,483 2,518 2,761 3,085 3,374
Operating Margin 32.95% 32.26% 33.15% 32.9% 31.81% 31.92% 32.23% 32.41%
Earnings before Tax (EBT) 1 1,100 1,243 1,644 1,611 1,509 1,878 2,312 2,665
Net income 1 1,164 1,295 1,618 1,706 1,651 1,831 2,194 2,440
Net margin 35.33% 31.67% 27.25% 22.61% 20.86% 21.17% 22.92% 23.43%
EPS 2 1.819 2.029 2.530 2.657 2.606 2.871 3.293 3.791
Free Cash Flow 1 462.3 -744.2 453.3 529.3 1,581 1,766 2,218 2,502
FCF margin 14.03% -18.2% 7.63% 7.01% 19.98% 20.41% 23.17% 24.03%
FCF Conversion (EBITDA) 38.33% - 21.57% 19.97% 57.37% 58.52% 65.63% 68.17%
FCF Conversion (Net income) 39.71% - 28.02% 31.02% 95.77% 96.42% 101.09% 102.56%
Dividend per Share 2 1.070 1.170 1.230 1.230 1.230 1.269 1.467 1.965
Announcement Date 07/03/20 26/02/21 24/02/22 16/02/23 13/03/24 - - -
1BRL in Million2BRL
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q2
Net sales 1 1,626 1,494 1,896 2,036 2,121 1,698 2,231 2,138 1,847 1,827 2,262 2,331 2,201 -
EBITDA 1 566.9 505.7 683.3 727.2 735 587.5 790.7 797.2 580.7 647.8 775.5 836.9 721.5 -
EBIT 1 530.9 294.5 644 684 686.6 535.8 734.1 735.8 512 579.4 726.5 782.6 654.8 -
Operating Margin 32.64% 19.72% 33.98% 33.6% 32.37% 31.55% 32.9% 34.41% 27.72% 31.72% 32.11% 33.57% 29.75% -
Earnings before Tax (EBT) 1 - - - - 440.8 270 471.8 474.3 293.3 373.8 487.9 549.3 469.3 -
Net income 1 640.4 349.5 455.8 466 431.7 339.4 504.4 499.5 307.8 391.5 449.5 491.5 400.1 -
Net margin 39.37% 23.4% 24.04% 22.89% 20.35% 19.99% 22.61% 23.36% 16.67% 21.44% 19.87% 21.08% 18.18% -
EPS 2 0.5720 0.5500 0.7200 0.7300 0.6475 0.5400 0.7900 0.7822 0.4999 0.6200 0.7576 0.8233 0.6811 0.9600
Dividend per Share 2 0.3000 0.3100 0.3078 - - - - - 0.3063 - - - 0.6156 -
Announcement Date 24/02/22 28/04/22 28/07/22 27/10/22 16/02/23 27/04/23 27/07/23 26/10/23 13/03/24 26/04/24 - - - -
1BRL in Million2BRL
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt 1 - 794 5,074 6,745 7,381 7,580 6,628 6,392
Net Cash position 1 844 - - - - - - -
Leverage (Debt/EBITDA) - 0.551 x 2.414 x 2.544 x 2.678 x 2.512 x 1.961 x 1.741 x
Free Cash Flow 1 462 -744 453 529 1,581 1,766 2,218 2,502
ROE (net income / shareholders' equity) 13.7% 14.4% 17% 16.7% 14.9% 13.9% 15.4% 16.8%
ROA (Net income/ Total Assets) 10.4% 8.88% 8.73% 7.83% 6.84% 7.52% 8.35% 9.31%
Assets 1 11,238 14,585 18,534 21,787 24,132 24,357 26,287 26,195
Book Value Per Share 2 13.80 14.60 15.40 16.80 18.20 19.90 21.70 23.50
Cash Flow per Share 1.290 1.850 2.190 3.190 - - - -
Capex 1 362 1,927 946 1,509 815 1,069 1,084 936
Capex / Sales 10.98% 47.13% 15.93% 20% 10.29% 12.36% 11.33% 8.99%
Announcement Date 07/03/20 26/02/21 24/02/22 16/02/23 13/03/24 - - -
1BRL in Million2BRL
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Year-on-year evolution of the Yield

Change in Enterprise Value/EBITDA

Ratings for Hypera S.A.

Trading Rating
Investor Rating
ESG Refinitiv
A-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
12
Last Close Price
29.79 BRL
Average target price
41.12 BRL
Spread / Average Target
+38.02%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

1st Jan change Capi.
HYPERA S.A. Stock Hypera S.A.
-15.72% 3.69B
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+26.62% 681B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+21.85% 556B
JOHNSON & JOHNSON Stock Johnson & Johnson
-4.96% 361B
MERCK & CO., INC. Stock Merck & Co., Inc.
+17.15% 325B
ABBVIE INC. Stock AbbVie Inc.
+5.36% 285B
ASTRAZENECA PLC Stock AstraZeneca PLC
+13.68% 235B
NOVARTIS AG Stock Novartis AG
+3.65% 199B
ROCHE HOLDING AG Stock Roche Holding AG
-11.12% 189B
PFIZER, INC. Stock Pfizer, Inc.
-4.10% 157B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. HYPE3 Stock
  4. Financials Hypera S.A.